

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

NCT06037811

Status	RECRUITING
Phase	Phase 2
Sponsor	Tom Appleton
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (13)

- Patients are deemed eligible for study participation if they meet all the following:
- Adult patients (age 18 or older)
- New (within the last 6 months prior to enrollment) inflammatory arthritis defined by any of the following at the time of screening (either on physical exam or by ultrasound) by a certified rheumatologist:
 - or more swollen joints OR
 - or more tenosynovitis OR
- ... and 8 more (see full listing online)

Exclusion (14)

- Patients are excluded if they meet any of the following:
- Previous diagnosis of inflammatory arthritis or other rheumatic disease (prior to current acute episode)
- Including but not limited to: rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, Sjogren's syndrome, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, systemic vasculitis, undifferentiated inflammatory arthritis, undifferentiated connective tissue disease
- Tenosynovitis, synovitis or enthesitis attributed to another cause, fracture or acute gout/CPPD flare.
- Presence of a contraindication to adalimumab therapy
- ... and 9 more (see full listing online)

Locations (1 total)

St. Joseph's Health Care, London, Ontario, Canada